Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250


Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.

Thies S, Friess M, Frischknecht L, Korol D, Felley-Bosco E, Stahel R, Vrugt B, Weder W, Opitz I, Soltermann A.

PLoS One. 2015 Sep 30;10(9):e0139312. doi: 10.1371/journal.pone.0139312. eCollection 2015.


Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.

Schramm A, Opitz I, Thies S, Seifert B, Moch H, Weder W, Soltermann A.

Eur J Cardiothorac Surg. 2010 Mar;37(3):566-72. doi: 10.1016/j.ejcts.2009.08.027. Epub 2009 Sep 24.


c-Met expression and MET amplification in malignant pleural mesothelioma.

Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, Smith CY, Molina JR, Peikert T, Roden AC.

Ann Diagn Pathol. 2016 Aug;23:1-7. doi: 10.1016/j.anndiagpath.2016.04.007. Epub 2016 Apr 30.


PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.

Bitanihirwe BK, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, Felley-Bosco E, Tsao MS, Allo G, de Perrot M, Seifert B, Moch H, Stahel R, Weder W, Opitz I.

J Thorac Oncol. 2014 Feb;9(2):239-47. doi: 10.1097/JTO.0000000000000055.


Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.

de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, Roberts H, Tsao MS, Leighl N, Keshavjee S, Johnston MR.

J Clin Oncol. 2009 Mar 20;27(9):1413-8. doi: 10.1200/JCO.2008.17.5604. Epub 2009 Feb 17.


CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.

Ortolan E, Giacomino A, Martinetto F, Morone S, Lo Buono N, Ferrero E, Scagliotti G, Novello S, Orecchia S, Ruffini E, Rapa I, Righi L, Volante M, Funaro A.

Oncotarget. 2014 Aug 15;5(15):6191-205.


Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey.

Kucukoner M, Ali Kaplan M, Inal A, Urakci Z, Abakay O, Cetin Tanrikulu A, Abakay A, Selim Sen H, Turkcu G, Senyigit A, Buyukbayram H, Isikdogan A.

J BUON. 2014 Jan-Mar;19(1):164-70.


How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?

Sharkey AJ, O'Byrne KJ, Nakas A, Tenconi S, Fennell DA, Waller DA.

Lung Cancer. 2016 Oct;100:5-13. doi: 10.1016/j.lungcan.2016.07.023. Epub 2016 Jul 22.


Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.

Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, Rozsas A, Renyi-Vamos F, Laszlo V, Grusch M, Filipits M, Scheed A, Jakopovic M, Samarzija M, Brcic L, Stancic-Rokotov D, Kern I, Rozman A, Dekan G, Klepetko W, Berger W, Glasz T, Dome B, Hegedus B.

Br J Cancer. 2015 Mar 3;112(5):783-92. doi: 10.1038/bjc.2015.9. Epub 2015 Jan 29.


Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma.

Meerang M, Bérard K, Friess M, Bitanihirwe BK, Soltermann A, Vrugt B, Felley-Bosco E, Bueno R, Richards WG, Seifert B, Stahel R, Weder W, Opitz I.

Mol Oncol. 2016 Oct;10(8):1255-65. doi: 10.1016/j.molonc.2016.06.005. Epub 2016 Jun 25.


BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.

McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN, Krausz T.

Hum Pathol. 2015 Nov;46(11):1670-8. doi: 10.1016/j.humpath.2015.06.024. Epub 2015 Jul 21.


Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions.

Lauk O, Hoda MA, de Perrot M, Friess M, Klikovits T, Klepetko W, Keshavjee S, Weder W, Opitz I.

Ann Thorac Surg. 2014 Nov;98(5):1748-54. doi: 10.1016/j.athoracsur.2014.05.071. Epub 2014 Aug 7.


Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.

Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A, Favaretto A.

Lung Cancer. 2011 Sep;73(3):351-5. doi: 10.1016/j.lungcan.2011.01.005. Epub 2011 Feb 5.


Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.

Tsutani Y, Takuwa T, Miyata Y, Fukuoka K, Hasegawa S, Nakano T, Okada M.

Ann Oncol. 2013 Apr;24(4):1005-10. doi: 10.1093/annonc/mds537. Epub 2012 Nov 7.


Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.

Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N.

Br J Cancer. 2014 Oct 28;111(9):1860-9. doi: 10.1038/bjc.2014.478. Epub 2014 Sep 4.


A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience.

Opitz I, Friess M, Kestenholz P, Schneiter D, Frauenfelder T, Nguyen-Kim TD, Seifert B, Hoda MA, Klepetko W, Stahel RA, Weder W.

J Thorac Oncol. 2015 Nov;10(11):1634-41. doi: 10.1097/JTO.0000000000000661. Review.


Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Mairinger FD, Vollbrecht C, Flom E, Christoph DC, Schmid KW, Kollmeier J, Popper HH, Mairinger T, Walter RFH.

Oncotarget. 2017 Jun 6;8(23):37502-37510. doi: 10.18632/oncotarget.16398.


Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.

de Reyniès A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sallé F, Copin MC, Hofman P, Cazes A, Andujar P, Imbeaud S, Petel F, Pairon JC, Le Pimpec-Barthes F, Zucman-Rossi J, Jean D.

Clin Cancer Res. 2014 Mar 1;20(5):1323-34. doi: 10.1158/1078-0432.CCR-13-2429. Epub 2014 Jan 17.


Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.

Nakas A, Waller D.

Eur J Cardiothorac Surg. 2014 Sep;46(3):380-5; discussion 385. doi: 10.1093/ejcts/ezt664. Epub 2014 Jan 30.


Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.

Frischknecht L, Meerang M, Soltermann A, Stahel R, Moch H, Seifert B, Weder W, Opitz I.

J Thorac Cardiovasc Surg. 2015 Jun;149(6):1539-46.e1. doi: 10.1016/j.jtcvs.2015.01.065. Epub 2015 Feb 12.

Supplemental Content

Support Center